Global Kidney Cancer Drugs Market by Type (Chromophobe, Clear Cell, Collecting Duct), Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies), Therapeutic Class - Forecast 2024-2030- Product Image

Sale

Global Kidney Cancer Drugs Market by Type (Chromophobe, Clear Cell, Collecting Duct), Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies), Therapeutic Class - Forecast 2024-2030

Report
189 Pages
March 2024
Region: Global
360iResearch™
ID: 4896747

UP TO €853EUR$875USD£729GBP OFF until Dec 31^st 2024

The Kidney Cancer Drugs Market size was estimated at USD 5.80 billion in 2023, USD 6.14 billion in 2024, and is expected to grow at a CAGR of 5.97% to reach USD 8.71 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Kidney Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Kidney Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Kidney Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen, Inc., AVEO Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Genentech, Inc., GlaxoSmithKline PLC, NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., Novartis AG, Pfizer Inc., Prometheus Laboratories Inc., Sun Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Kidney Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Chromophobe
- Clear Cell
- Collecting Duct
- Oncocytic
- Papillary
Pharmacologic Class
- Angiogenesis Inhibitors
- Cytokine Immunotherapy
- Monoclonal Antibodies
- MTOR Inhibitors
Therapeutic Class
- Immunotherapy
- Targeted Therapy

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Kidney Cancer Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Kidney Cancer Drugs Market?
What are the technology trends and regulatory frameworks in the Kidney Cancer Drugs Market?
What is the market share of the leading vendors in the Kidney Cancer Drugs Market?
Which modes and strategic moves are suitable for entering the Kidney Cancer Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Kidney Cancer Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Proliferation in the number of people suffering from cancer
5.1.1.2. Growing geriatric population with hypertension and diabetes
5.1.1.3. Increasing lifestyle changes including smoking, drinking, and consumption of processed food
5.1.2. Restraints
5.1.2.1. Risk of complications associated with treatment
5.1.3. Opportunities
5.1.3.1. Availability of novel drugs and the presence of a strong pipeline
5.1.3.2. Increasing research and development investment coupled with collaborations among manufacturers
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Kidney Cancer Drugs Market, by Type

6.1. Introduction
6.2. Chromophobe
6.3. Clear Cell
6.4. Collecting Duct
6.5. Oncocytic
6.6. Papillary

7. Kidney Cancer Drugs Market, by Pharmacologic Class

7.1. Introduction
7.2. Angiogenesis Inhibitors
7.3. Cytokine Immunotherapy
7.4. Monoclonal Antibodies
7.5. MTOR Inhibitors

8. Kidney Cancer Drugs Market, by Therapeutic Class

8.1. Introduction
8.2. Immunotherapy
8.3. Targeted Therapy

9. Americas Kidney Cancer Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Kidney Cancer Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Kidney Cancer Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Amgen, Inc.
13.1.2. AVEO Pharmaceuticals, Inc.
13.1.3. Bayer AG
13.1.4. Bristol-Myers Squibb Company
13.1.5. Eisai Co., Ltd.
13.1.6. Exelixis, Inc.
13.1.7. Genentech, Inc.
13.1.8. GlaxoSmithKline PLC
13.1.9. NanoString Technologies, Inc.
13.1.10. NeoGenomics Laboratories, Inc.
13.1.11. Novartis AG
13.1.12. Pfizer Inc.
13.1.13. Prometheus Laboratories Inc.
13.1.14. Sun Pharmaceutical Industries Limited
13.1.15. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. KIDNEY CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. KIDNEY CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. KIDNEY CANCER DRUGS MARKET DYNAMICS
FIGURE 7. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2023 VS 2030 (%)
FIGURE 10. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 12. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. KIDNEY CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 12. KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 17. KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 29. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 31. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 34. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 46. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 48. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 51. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 57. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 75. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 85. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 88. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 91. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 94. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 97. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 101. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 103. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 112. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 113. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 115. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 118. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 139. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 146. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 147. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 148. KIDNEY CANCER DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Amgen, Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
Genentech, Inc.
GlaxoSmithKline PLC
NanoString Technologies, Inc.
NeoGenomics Laboratories, Inc.
Novartis AG
Pfizer Inc.
Prometheus Laboratories Inc.
Sun Pharmaceutical Industries Limited
Thermo Fisher Scientific Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	189
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 6.14 Billion
Forecasted Market Value ( USD ) by 2030	$ 8.71 Billion
Compound Annual Growth Rate	5.9%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3291EUR$3,374USD£2,810GBP €3657EUR$3,749USD£3,122GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4169EUR$4,274USD£3,560GBP €4632EUR$4,749USD£3,955GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5047EUR$5,174USD£4,309GBP €5608EUR$5,749USD£4,788GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5925EUR$6,074USD£5,059GBP €6583EUR$6,749USD£5,621GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7681EUR$7,874USD£6,558GBP €8534EUR$8,749USD£7,286GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Kidney Cancer Drugs: Global Strategic Business Report

Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Global Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast 2024-2034: Market By Cancer Type; By Component (Drugs (Therapeutic Class Pharmacologic Class, Diagnostics; By End-user; and By Region

Kidney Cancer Therapeutics and Diagnostics Market by Component, Cancer Types, Application, and Region 2023-2028

Kidney Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

About the Kidney Cancer Drugs Market